Gold bars to be exempt from tariffs, White House clarifies
Investing.com -- Kenvue Inc. shares fell 3.4% in premarket trading after the consumer health company reported second-quarter results that missed analyst expectations across the board and lowered its full-year outlook.
The maker of brands like Tylenol and Listerine posted adjusted earnings per share of $0.29 for the quarter ended June 29, falling short of the $0.35 analysts had expected. Revenue came in at $3.84 billion, significantly below the consensus estimate of $4.18 billion.
The disappointing results prompted Kenvue (NYSE:KVUE) to cut its full-year 2025 earnings forecast to between $1.00 and $1.05 per share, below the $1.13 analysts had projected. The company previously guided for adjusted earnings per share to be about flat year-over-year, around $1.14.
Furthermore, Kenvue now expects both net sales and organic sales to decline in the low single digits for the year.
"Kenvue has a strong portfolio of world-class, category-defining brands. We are actively focused on improving execution and performance, while advancing the comprehensive strategic alternatives review, to deliver our inherent value," said Kirk Perry, Interim Chief Executive Officer, who took over the role in July.
The second-quarter performance reflected continued challenges for the company, with organic sales declining 4.2% YoY. The company attributed the weakness to unfavorable pricing, volume declines, weak allergy and sun care seasons in North America, trade inventory fluctuations, and changes in shipment timing in China.
Adjusted operating income margin was nearly flat at 22.7% compared to 22.8% in the same quarter last year, while adjusted gross profit margin contracted to 60.9% from 61.6% a year earlier.
Kenvue’s board continues to advance its ongoing comprehensive review of strategic alternatives, which could include optimizing the company’s brand portfolio while improving execution to accelerate profitable growth.